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The aim of the work was the synthesis of gold nanoparticles (GNP) of different sizes and the estimation of their biological activity 
in vitro and in vivo. Materials and Methods: Water dispersions of gold nanoparticles of different sizes have been synthesized by Da-
vis method and characterized by laser-correlation spectroscopy and transmission electron microscopy methods. The GNP interac-
tion with tumor cells has been visualized by confocal microscopy method. The enzyme activity was determined by standard bio-
chemical methods. GNP distribution and content in organs and tissues have been determined via atomic-absorption spectrometry 
method; genotoxic influence has been estimated by “Comet-assay” method. Results: The GNP size-dependent accumulation 
in cultured U937 tumor cells and their ability to modulate U937 cell membrane Na+,K+-АТР-ase activity value has been revealed 
in vitro. Using in vivo model of Guerin carcinoma it has been shown that GNP possess high affinity to tumor cells. Conclusions: 
Our results indicate the perspectives of use of the synthesized GNP water dispersions for cancer diagnostics and treatment. It’s nec-
essary to take into account a size-dependent biosafety level of nanoparticles .
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Metal nanoparticles are a principally new class 
of compounds that possess  significant biological 
activity and are potentially perspective for diagnos­
tics and treatment of diseases of different ethiology, 
especially cancer [1–5].
Gold nanoparticles, in comparison with other me­
tals, are characterized by unique physical, chemical, 
biological properties and functional activity [6–10]. The 
nanoparticle size and shape substantially define their 
properties [11–15]. High affinity to tumor cells, surface 
modification ability and special optical properties create 
the basis for effective usage of GNP as vectors for target 
antitumor drug delivery [16, 17], in cancer phototermal 
therapy [18–20], as contrasting agents in magnetic 
resonance and computer tomography [21, 22].
The aim of this work was the synthesis of gold 
nanoparticles with different sizes and estimation 
of their biological activity in vitro and in vivo.
MATERIALS AND METHODS
GNP have been synthesized by Davis’ method from 
the tetrachloroauric (III) acid (HAuCl4 · 3H2O) (≥99.9% 
trace metals basis, Sigma­Aldrich) [23] and have been 
characterized by their size using laser­correlation 
spectroscopy (Zetasizer­3, Malvern Instruments Ltd, 
UK) and transmission electron microscopy (JEM­1230, 
JEOL, Japan) methods.
The concentrat ion of  obtained GNP was 
38.6 μg/ml by metal for each size of preparations.
For in vitro experiments U937 (human leukemic 
monocyte lymphoma) cell line as model of tumor cells 
has been used. The cell line was obtained from the 
Bank of Cell Lines from Human and Animal Tissues, 
R.E. Kavetsky Institute of Experimental Pathology, 
Oncology and Radiobiology of NAS of Ukraine. The 
cell’ viability has been estimated by trypan blue exclu­
sion test. The quantity of alive cells was > 90 % in all 
experiments.
The GNP interaction with tumor cells has been 
visualized by confocal microscopy method (LSM 
510 META, Carl Zeiss, Germany).
U937 cell total membrane fraction isolation has 
been carried out by the  method [24]. Protein content 
in membrane preparations has been evaluated by the 
method of Lowry [25].
Na+,K+­АТР­ase activity (E.C. 3.6.1.3) of U937 cell 
membrane fraction has been measured by method 
[26] at 37 °С in 1 ml incubation medium (50 мМ Tris­
HCl, 5 мМ MgCl2, 100 мМ NaCl, 20 мМ KCl, 3 мМ АТР 
(рН=7.5)). Membrane aliquot (15–20 μg of protein) 
was added into incubation medium, incubated for 
10 min and stopped by addition of 1 ml 10% trichlo­
racetic acid. The phosphorus content has been mea­
sured by Fiske­Subbarow method [27]. For estimation 
of GNP influence on the enzyme activity the membrane 
fraction protein (150–200 μg) was mixed with GNP 
3 min before the incubation (at concentration range 
of 0.11–1.1 μg/ml by metal). 20 мМ Тris­HCl buffer 
has been added in control sample instead of GNP.
For in vivo experiments white inbred rats (males 
and females) with average weight of 180–230 g from 
vivarium of R.E. Kavetsky Institute of Experimental Pa­
thology, Oncology and Radiobiology, have been used.
All experiments with laboratory animals using have 
been carried out in compliance with “Guide for the Care 
and Use of Laboratory Animals”.
The transplantation of Guerin carcinoma to the 
laboratory rats has been carried out subcutaneously 
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on the back using 23% suspension of tumor tissue 
in physiological solution. The study of GNP influence 
on the tumor growth in vivo has been initiated when 
tumor size reached ~ 30 mm × 40 mm × 20 mm.
Experimental tumor­bearing animals have been kept 
at the standard regimen and housed  in four groups: 
control group — 3 animals without treatment; and 
3 experimental groups (8 animals per group) treated with 
single intravenous GNP injection (1 ml of GNP, 38.6 μg/
ml by metal) on the basis of 20, 30 and 45 nm preparations.
The euthanasia of animals from control and experi­
mental groups has been performed 1 h after injection 
(4 animals from each experimental group) and 24 h after 
administration.
The GNP distribution in tissues (thymus, brain, 
spleen, liver, kidneys, adrenal glands, lungs, heart and 
tumor) has been studied using the atomic­absorption 
spectrometry method [28] on the complex “Graphit 
­2” (Ukraine). The sensitivity of the method is 6 ng/ml.
The GNP DNA­damaging activity in vivo has been 
estimated by “Comet­assay” method (alkaline gel­elec­
trophoresis of isolated eukaryotic cells) [29]. Cell isolation 
from liver, kidneys, spleen, bone marrow, intestine and tu­
mor tissue has been performed using standard protocols.
The statistical analysis of the obtained data has 
been carried out using Student’s t­criterion [30]. The 
differences p < 0.05 were considered as significant.
RESULTS AND DISCUSSION
Water dispersions of coagulation­resistant gold 
nanoparticles have been synthesized for analysis 
of their activity in vitro and in vivo. Average sizes 
of synthesized GNP preparations were 10; 20; 30 and 
45 nm according to the data of laser­correlation spec­
troscopy and transmission electron microscopy. The 
electron­microscopic image of synthesized 10 nm gold 
nanoparticles is presented on Fig. 1.
Fig. 1. Electron­microscopic image of synthesized gold nanopar­
ticles with average size of 10 nm (JEM­1230, JEOL, Japan)
The method of synthesis used for the GNP production 
is based on the conversion of dissolved gold (water solu­
tion of tetrachloroauric acid) into insoluble condition with 
subsequent aggregation and crystallization of insoluble 
particles which form dispersed phase. The peculiarities 
of gold nanoparticle structure play an important role 
in conditions of their contact with different types of bio­
logical objects. The different quantity of constituent at­
oms, depending on the size of nanoparticles, bind to the 
surface: the percentage of surface atoms is higher for 
smaller particles. The increase of active surface area per 
mass, changes in interatomic distance and crystal lattice 
period affect the nanoparticle ability to penetrate into the 
cell, their biological activity as well as chemical, physical 
and pharmacological properties [31, 32].
High level of the GNP accumulation in U937 tumor 
cells has been determined by confocal microscopy 
by layer­by­layer scanning (Fig. 2).
Fig. 2. Confocal­microscopic image of U937 tumor cells (cell 
concentration is 106 cells/ml) after 3 min incubation with 30 nm 
gold nanoparticles at the concentration of 12.7 μg/ml by metal. 
Z­scanning with 1 μm step; GNP maximum accumulation is pre­
sented as red staining (LSM 510 META «Carl Zeiss», Germany)
The most effective GNP accumulation by U937 tu­
mor cells has been observed for 20 and 30 nm gold 
nanoparticles.
In vitro biological activity of synthesized gold 
nanoparticles is estimated through measuring the 
values of Na+,К+­АТР­ase and Mg2+­АТР­ase activi­
ties of membrane fraction  of U937 cells treated with 
GNP. The obtained results have demonstrated the 
dependence of such activity from nanoparticles size 
(Fig. 3, curves 1–4). GNP with average size of 10 nm in all 
studied concentrations (0.11–1.1μg Au/ml) inhibited the 
enzyme activity by 70% in comparison with control cells 
(curve 1), GNP with 20 nm diameter — by 20 % (curve 
2). At the same time GNP with average size 30 nm and 
45 nm in concentration range 0.11–1.10μg Au/ml stimu­
lated Na+,K+­АТР­ase activity by 30–40 % (curve 3), and 
20–40% (curve 4), respectively.
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Fig. 3. Changes of U937 tumor cell membrane fraction Na+,К+­
АТР­ase activity value (А/А0, %) upon the influence of gold 
nanoparticles with average sizes: 1–10 nm, 2–20 nm, 3–30 nm, 
4–45 nm. (M±m; n=5, p < 0.05 compared to control — А0). Native 
Na+,К+­АТР­ase activity value is considered as 100 % (control)
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T h u s ,  i n  G N P  c o n c e n t r a t i o n  r a n g e 
of 0.11–0.28 μg Au/ml (45nm) we have registered 20% 
elevation of the enzyme activity, while in concentration 
range 0.28–0.55 μg Au/ml GNP this value increased 
from 20% to 40% and was equal to 40% in concentra­
tion range of 0.55–1.10 μg Au/ml.
However, treatment of U937 cells with GNP (in all in­
vestigated sizes) has no significant influence on Mg2+­
АТР­ase activity of cell membrane fraction.
In vivo study of GNP biological activity after their 
intravenous injection is important for estimation of GNP 
perspective usage in cancer diagnostics and therapy. 
That’s why we have estimated the patterns of GNP 
distribution and accumulation in organs and tissues 
of experimental animals.
Via atomic absorption spectrometry the GNP 
distribution and accumulation in organs and tissues 
of experimental normal animals and Guerin carcinoma 
bearing animals have been studied. For gold content 
analysis thymus, brain, spleen, liver, kidneys, adrenal 
glands, lungs, heart and tumor tissue of experimental 
animals have been examined 1 and 24 h after single 
GNP i.v. injection. It has been revealed that the gold 
is not present in studied organs of normal experimental 
animals either in 1 h nor 24 h after GNP injection. It may 
be suggested that tumor influences gold nanopar­
ticles distribution in tumor­bearing organism resulting 
in their accumulation in non tumor tissue in contrast 
to the non­tumor­bearing host.
However, in studied organs of tumor­bearing animals 
the picture was different. 20 nm GNP distribution and ac­
cumulation in different organs of experimental animals 
are demonstrated in Table 1. In tumor bearing animals 
1 h after GNP injection gold content values were as fol­
lows: in brain — 26.09±3.15 ng Au/g tissue, kidneys — 
51.40±6.23 ng Au/g tissue, spleen — 60.00±5.78 ng Au/g tis­
sue, and liver — 37.60±4.07 ng Au/g tissue.
Table 1. Accumulation of GNP with average size of 20 nm in organs and 
tissues of Guerin carcinoma bearing animals after intravenous injection 
of nanoparticles (1 ml)
Target organ
Concentration of gold, ngAu/g tissue
Control group 1 h after GNP in-jection
24 h after GNP 
injection
Tumor - 78.90±5.27 31.70±2.69
Thymus - - -
Brain - 26.09±3.15 -
Lungs - - -
Heart - - -
Adrenal glands - - -
Kidneys - 51.40±6.23 -
Spleen - 60.00±5.78 -
Liver - 37.60±4.07 12.70±1.92
Note: “-” — gold content below detection limits (M ± m; n = 4, p < 0.05).
In 24 h after GNP injection the level of gold accumu­
lation in liver, spleen and kidneys has been substantial­
ly decreased and amounted to 12.7±1.92 ng Au/g tis­
sue for liver and was absent in spleen and kidneys. 
These data demonstrate the principal role of these 
organs in detoxication and clearance of GNP from 
the organism.
The peculiarities of GNP accumulation in brain 
of tumor­bearing animals have shown their ability 
to penetrate through hematoencephalic barrier what 
can be used in diagnostics and target therapy.
The highest level of the gold accumulation 
(78.90±5.27 ng Au/g tissue), comparatively with 
other organs, has been registered in tumors 
in 1 h after GNP  injection, while in 24 h it amounted 
to 31.7±2.69 ng Au/g tissue, what was twice higher 
than its residual concentration in liver.
Thus, the GNP high clearance rate in the conditions 
of their i.v. injection to normal animals has been demo­
nstrated while as GNP predominant accumulation has 
been determined in tumor tissue at both time points 
(1 and 24 h after intravenous injection).
GNP usage in diagnostics or therapy should 
be validated through their biosafety marker tests 
in vitro and in vivo. One of most sensitive marker tests 
of biosafety is genotoxicity test, which reveals agent 
DNA­damaging influence. For this purpose we have 
used “Comet assay” method.
The GNP genotoxicity, depending on their size, 
has been analyzed earlier [33, 34] in vitro and in vivo. 
The 20 nm GNP genotoxic influence on kidney cells 
of tumor­bearing rats in 1 h after single GNP intrave­
nous injection has resulted in 24.04% of DNA in comet 
tail versus 0.24% for negative control (Table 2, Fig. 4). 
These data evidence on potential risk of 20 nm GNP 
injection for normal organs.
Table 2. GNP genotoxicity evaluation in organs and tissues of Guerin car-
cinoma-bearing animals 1 h after intravenous injection of nanoparticles
Target organ
% of DNA in co-
met tail, negative 
control
% of DNA in comet tail in GNP-adminis-
tered animals
20 nm 30 nm 45 nm
Liver 0.27 0.44 0.32 0.35
Kidneys 0.24 24.04 0.27 0.33
Spleen 0.23 0.27 0.27 0.27
Tumor 0.92 apoptosis 0.91 0.93
Fig. 4. Electrophoretic image of kidney cell damaged DNA 
(DNA­comet) 1 h after i.v. injection of 20 nm gold nanoparticles 
to tumor­bearing animals 
1 h after 20 nm GNP injection the apoptosis rate 
of  tumor cells yielded up to 80%. It is the evidence 
of total tumor cells death.
The 30 and 45 nm GNP injection didn’t cause DNA 
damage in organs and tumor tissue of experimental 
animals in 1 h after i.v. injection. In other words, 30 and 
45 nm nanoparticles revealed biosafety in such test.
In 24 h after i.v. injection of 20, 30 and 45 nm GNP 
there has been registered no genotoxic influence 
(Table 3).
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Table 3. GNP genotoxicity evaluation in organs and tissues of Guerin car-
cinoma-bearing animals 24 h after intravenous injection of nanoparticles
Target organ
% of DNA in co-
met tail, ne gative 
control
% of DNA in comet tail in GNP-adminis-
tered animals
20 nm 30 nm 45 nm
Liver 0.31 0.41 0.43 0.42
Kidneys 0.29 0.57 0.52 0.56
Spleen 0.25 0.25 0.27 0.32
Tumor 0.71 0.83 0.77 0.71
So, the high specific size­dependent biological 
activity in vitro and in vivo of synthesized water disper­
sions of GNP has been revealed. In vitro data show 
that synthesized gold nanoparticles possessed by ex­
pressed size­dependent modulation of membrane 
Na+,K+­АТР­ase activity in U937 tumor cells. In vivo 
results indicate that gold nanoparticles possess high 
affinity to tumor cells after their i.v. injection to ex­
perimental animals. These in vitro and in vivo results 
point on the perspectiveness of GNP use in cancer 
diagnostics and treatment, although it is necessary 
to take into account the size­dependent biosafety level 
of GNP concerning normal organs.
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